Hematological Malignancies

PRIMA: Progression-free survival

Rituximab maintenance significantly reduced the risk of progression by 50%

Progression-free rate 0.8 0.6 0.4 0.2 0 1.0

82%

Rituximab maintenance N=505

66%

Observation N=513

stratified HR=0.50 95% CI 0.39; 0.64 p <.0001

Time (months)

0

6

12

18

24

30

36

Patients at risk 505 513

472 469

443 411

336 289

230 195

103

18 15

82

Salles G, et al. Lancet 2011; 377:42–51